(Total Views: 558)
Posted On: 04/15/2020 4:45:05 PM
Post# of 155689
“OK , is that the study we are doing 2:1 placebo.....?????”
Yes, he’s referring to the phase 2/3 for severely ill patients. I’m glad BP pointed this out as I’m sure there are few BPs or biotechs willing to target the most ill COVID patients because of the difficulties of doing so. But CYDY did because of BP’s knowledge of leronlimab’s MOA and his confidence that it can reduce the mortality rate.
“Who can explain reason for placebo here , please listen, was my understanding not right ????“
(Bird chirping). No one can answer that question. The FDA is stuck in their old ways. I can’t imagine it would be hard to get get retrospective data from 125 severely ill COVID19 patients from other hospitals and use that as the placebo arm.
Yes, he’s referring to the phase 2/3 for severely ill patients. I’m glad BP pointed this out as I’m sure there are few BPs or biotechs willing to target the most ill COVID patients because of the difficulties of doing so. But CYDY did because of BP’s knowledge of leronlimab’s MOA and his confidence that it can reduce the mortality rate.
“Who can explain reason for placebo here , please listen, was my understanding not right ????“
(Bird chirping). No one can answer that question. The FDA is stuck in their old ways. I can’t imagine it would be hard to get get retrospective data from 125 severely ill COVID19 patients from other hospitals and use that as the placebo arm.
(1)
(0)
